glp-1 ozempic Another Weight-Loss Trial Win for Weekly Drug More people with type 1

So far, Novo is furthest ahead in developing an obesity pill

Kristyn Gumpper-Fedus, PhD, for refining a draft of the Figure into its final form

PMCID: PMC12210098

Novo is essentially trying to innovate past its own product before the generics get there upgrade the semaglutide franchise into something new enough that a generic of the old thing becomes less relevant

Ecdysterone Monitoring Continues Ecdysterone , a compound found in some plants and marketed in supplements for muscle-building effects, remains on the monitoring program

Why? Fasting is a common strategy during GLP-1 therapy, but hunger during fasting periods can derail progress